论文部分内容阅读
协和发酵工业公司的抗癌新药日本协和发酵工业公司（Ｋ·Ｈａｋｋｏ）计划向欧洲癌症研究及治疗中心（ＥＯＲＴＣ）申请名为Ｅ０－９的抗癌新药世界范围内的生产权及市场经营权、开发权。他们合作研究Ｅ０－９，并试图在１９９４年进行新药的Ⅱ期临床试验。表明Ｅ０－９可...
Kyowa Hakko Kako Co., Ltd. plans to apply to the European Center for Cancer Research and Treatment (EORTC) for worldwide production and marketing rights of the new anticancer drug E0-9, Development right. They collaborated on E0-9 and are trying to phase II the new drug in 1994. E0-9 can be ...